Sentiment for Array Biopharma Inc (NASDAQ:ARRY)
Array Biopharma Inc (NASDAQ:ARRY) institutional sentiment decreased to 0.8 in Q3 2015. Its down -0.45, from 1.25 in 2015Q2. The ratio worsened, as 79 institutional investors started new and increased equity positions, while 63 decreased and sold positions in Array Biopharma Inc. The institutional investors in our partner’s database reported: 152.30 million shares, up from 139.95 million shares in 2015Q2. Also, the number of institutional investors holding Array Biopharma Inc in their top 10 equity positions decreased from 5 to 1 for a decrease of 4. Sold All: 19 Reduced: 44 Increased: 55 New Position: 24.
Array BioPharma Inc. is a biopharmaceutical firm focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer. The company has a market cap of $435.82 million. The Company’s wholly owned clinical stage drugs include Filanesib in Phase II clinical trials, is indicated for Kinesin spindle protein , inhibitor for MM; ARRY-797 in Phase II clinical trials, indicated for p38 inhibitor for Lamin A/C-related dilated cardiomyopathy (LMNA-DCM); ARRY-502 in Phase II clinical trials, indicated for CRTh2 antagonist for asthma, and ARRY-614 in Phase I clinical trials, is indicated for p38/Tie2 dual inhibitor for myelodysplastic syndromes (MDS). It currently has negative earnings.
The stock increased 1.35% or $0.04 on March 4, hitting $3. Array Biopharma Inc (NASDAQ:ARRY) has declined 47.83% since July 30, 2015 and is downtrending. It has underperformed by 42.67% the S&P500.
Analysts await Array Biopharma Inc (NASDAQ:ARRY) to reports earnings on May, 2. They expect $-0.14 earnings per share, down 27.27% or $0.03 from last year’s $-0.11 per share. After $-0.17 actual earnings per share reported by Array Biopharma Inc for the previous quarter, Wall Street now forecasts -17.65% EPS growth.
According to Zacks Investment Research, “Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. The company’s proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas.”
Bvf Inc Il holds 8.92% of its portfolio in Array Biopharma Inc for 9.68 million shares. First Light Asset Management Llc owns 988,589 shares or 2.23% of their US portfolio. Moreover, Deerfield Management Co has 1.72% invested in the company for 9.73 million shares. The California-based Redmile Group Llc has invested 1.71% in the stock. Longwood Capital Partners Llc, a California-based fund reported 480,020 shares.#img1#
Since May 12, 2015, the stock had 1 insider buy, and 0 insider sales for $3.58 million net activity. Redmile Group - Llc bought 782,592 shares worth $3.58M. Baum Charles M sold 25,000 shares worth $184,483.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.